Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7, 2017
October 10 2017 - 04:01PM
Business Wire
Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of
innovative treatments for aortic disorders, today announced that it
will report financial results for the third quarter of fiscal year
2017 after the market close on Tuesday, November 7, 2017. The
Company’s management will host a conference call at 4:30 p.m. ET
that same day to discuss the results.
To participate in the conference call, dial 877-407-9716
(domestic) or 201-493-6779 (international).
This conference call will also be webcast and can be accessed
from the “Investors” section of the Company’s website at
www.endologix.com. The webcast replay of the call will be available
at the same site approximately one hour after the end of the
call.
A recording of the call will also be available from 7:30 p.m. ET
on Tuesday, November 7, 2017, until 11:59 p.m. ET on Tuesday,
November 14, 2017. To hear this recording, dial 844-512-2921
(domestic) or 412-317-6671 (international) and enter the passcode
13672121.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's focus is
endovascular stent grafts for the treatment of abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the
aorta, the largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and,
if left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is
approximately 80%, making it a leading cause of death in the
United States. For more information, visit www.endologix.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171010006476/en/
Investors:Endologix, Inc.Vaseem Mahboob, CFO949-595-7200
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Mar 2023 to Mar 2024